Gregory Clarke to Cost-Benefit Analysis
This is a "connection" page, showing publications Gregory Clarke has written about Cost-Benefit Analysis.
Connection Strength
0.694
-
Cost-effectiveness of Cognitive Behavioral Therapy for Depressed Youth Declining Antidepressants. Pediatrics. 2018 02; 141(2).
Score: 0.576
-
The ReThink study: a 3-arm parallel randomized trial of cognitive bias modification, with and without adherence promotion, for adolescent anxiety disorder: trial design and protocol. BMC Psychiatry. 2019 10 22; 19(1):306.
Score: 0.041
-
Rationale, design, and baseline data for a multicenter randomized clinical trial comparing depression screening strategies after acute coronary syndrome: The comparison of depression identification after acute Coronary Syndromes-Quality of Life and Cost Outcomes (CODIACS-QOL) trial. Contemp Clin Trials. 2019 09; 84:105826.
Score: 0.040
-
Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011 Mar; 68(3):253-62.
Score: 0.022
-
Cost-effectiveness of an intervention to prevent depression in at-risk teens. Arch Gen Psychiatry. 2005 Nov; 62(11):1241-8.
Score: 0.015